IFNB1 and colitis: Additionally, it would be of interest to study the effects of La-IFN-β administration in other disease contexts, such as in a DSS treatment model or other models of colitis, or to see if the previously reported protective benefits of recombinant IFN-β in experimental colitis is dose dependent.